
NRSN Stock Forecast & Price Target
NRSN Analyst Ratings
Bulls say
NeuroSense Therapeutics is effectively advancing its development pipeline for PrimeC, demonstrating a significant 29.2% slowing of disease progression in ALS patients during its Phase 2b PARADIGM study, which aligns with favorable reported safety and tolerability outcomes. The potential regulatory approval in Canada by 2026 is expected to enhance opportunities for regional commercial partnerships, providing avenues for non-dilutive capital. With continued regulatory progress and positive clinical results, the likelihood of strategic partnerships in North America and Europe is increasing, signaling a robust outlook for the company's future prospects.
Bears say
The financial outlook for NeuroSense Therapeutics appears negative, primarily due to concerns over dwindling cash reserves, which may necessitate a capital raise. This potential need for additional financing could dilute existing shareholders' equity and create uncertainty regarding the company's financial stability. Moreover, the reliance on the commercial success of its lead product candidate, PrimeC, amidst a competitive biotechnology landscape further complicates its revenue prospects.
This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.
NRSN Analyst Forecast & Price Prediction
Start investing in NRSN
Order type
Buy in
Order amount
Est. shares
0 shares